文拉法辛缓释剂对抑郁伴发焦虑障碍患者的疗效

目的 研究文拉法辛缓释剂对抑郁伴发焦虑障碍患者的治疗效果.方法 对20例抑郁症伴发焦虑障碍患者以文拉法辛缓释剂治疗6周,平均剂量为(154±46)mg/d.在治疗前及第1、2、4、6周末评定汉密尔顿抑郁量表(17项,HAMD)和汉密尔顿焦虑量表(HAMA),并监测血压,记录不良反应.结果 文拉法辛缓释剂对抑郁伴发焦虑障碍效果良好,HAMD评分自第1周起均有显著改善,且一直持续至治疗第6周末.HAMA评分自第1周起也有显著改善.不良反应轻微.结论 文拉法辛缓释剂抗抑郁及抗焦虑作用尚可,可用于抑郁症伴发焦虑障碍的治疗.

A Study on Efficacy of Extended Release Venlafaxine in Treatment of Co-occurring Depression and Anxiety Disorder

Objective To investigate the efficacy of extended release venlafaxine (venlafaxine-XR) in treatment of co-occurring depression and anxiety disorder. Methods 20 patients were enrolled to receive venlafaxine-XR for 6weeks. HAMD and HAMA were adopted to evaluate the efficacy. Safety was estimated by TESS, laboratory and physical examination. Results After 6 weeks treatment, the result based on the reduction rate of HAMD and HAMA showed venlafaxine-XR was effective. The HAMD and HAMA scores decreased significantly from the first weekend to the sixth weekend (P<0.01). The adverse effects were mild. Conclusions Venlafaxine-XR may be effective in co-occurring depression and anxiety disorder.